ASX:NTI Neurotech International (NTI) Stock Price, News & Analysis → Mysterious Gold Leverage Just Announced (From Stansberry Research) (Ad) Free NTI Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Neurotech International alerts: Email Address Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. About Neurotech International Stock (ASX:NTI)Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company is focused on development and commercializing Mente platform, a platform technology to monitor and play role in home-based therapies. Its products includes Mente Autism for the diagnosis and treatment of autism. It also engages in executing of medical research projects; and developing of technological devices. Neurotech International Limited was incorporated in 2016 and is based in Nedlands, Australia.Read More Ad Stansberry ResearchMysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.Find out what it is and see how you can get in with just a few dollars. NTI Stock News HeadlinesApril 17, 2024 | msn.comNeurotech’s Phase 2/3 autism trial meets primary endpointApril 10, 2024 | msn.comNeurotech hits new milestone in Phase II/III autism trial after treating last patientApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.April 5, 2024 | tmcnet.comNeuroVigil, World's Most Valuable Neurotech, Launches iBrain™ in USApril 5, 2024 | tmcnet.comNeuroVigil, World's Most Valuable Neurotech Company, Launches in USMarch 13, 2024 | msn.comNeurotech extends clinical trials for the $US2bn Rett Syndrome marketFebruary 27, 2024 | finance.yahoo.comNeurotech International's (ASX:NTI) investors will be pleased with their massive 340% return over the last five yearsFebruary 13, 2024 | msn.comMarket Highlights: Chipmaker Arm up 29pc, Bitcoin tops US$50k, and 5 ASX small caps to watch todayApril 25, 2024 | Stansberry Research (Ad)Mysterious Gold Leverage Just AnnouncedWorld's biggest multibillionaire investor group is buying THIS by the tons Most folks have completely missed the fact that there's one group of investors so powerful they're literally buying ONE THING by the tons… Stacking it in their locked vaults on pallets in record numbers.February 7, 2024 | morningstar.comMicroPort NeuroTech Ltd 02172January 28, 2024 | msn.comNeurotech gets green light to start phase I/II cerebral palsy trialJanuary 24, 2024 | msn.comNeurotech moves to show economic advantage of autism treatment as Phase II/III trial results due soonJanuary 16, 2024 | msn.comWhat’s in store for 2024: Neurotech InternationalDecember 26, 2023 | msn.comPart 1: ASX biotechs with catalysts looking to pop in 2024December 18, 2023 | msn.comNeurotech completes recruitment in Phase 2/3 autism spectrum disorder trialDecember 3, 2023 | msn.comNeurotech to extend Phase 2/3 autism spectrum disorder trial to adultsOctober 8, 2023 | msn.comNeurotech treatment looks to be making a difference in children with PANDAS/PANS in Phase I/II clinical trialSeptember 22, 2023 | businesswire.comMotif Neurotech Conducts First-in-human Brain Stimulation With Millimeter-sized Implantable Device for Treatment-resistant DepressionSeptember 7, 2023 | benzinga.comNorthern Trust Asset Management Names New CIO of Global Asset AllocationAugust 14, 2023 | msn.comMoneyTalks: Merchant Group’s Andrew Chapman has his eye on these diagnostic biotech stocksJune 27, 2023 | finance.yahoo.comHere's Why We're Not Too Worried About Neurotech International's (ASX:NTI) Cash Burn SituationJune 21, 2023 | uk.investing.comNeurotech International Ltd (NTI)March 17, 2023 | msn.comASX Health Stocks: Neurotech says NTI164 works well in 11 autistic children after 52 weeks of treatmentMarch 12, 2023 | proactiveinvestors.com.auArovella Therapeutics recruits biotech stalwart as non-executive chairJanuary 15, 2023 | au.finance.yahoo.comNeurotech International Limited (NTI.AX)January 14, 2023 | benzinga.comNeurotech Devices Market is projected to grow at a CAGR of 13.78% by 2033: Visiongain Reports LtdJanuary 14, 2023 | finance.yahoo.comWe Think Neurotech International (ASX:NTI) Needs To Drive Business Growth CarefullySee More Headlines Receive NTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurotech International and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Medical Devices Sub-IndustryN/A Current SymbolASX:NTI CUSIPN/A CIKN/A Webwww.neurotechinternational.com Phone61 8 9389 3130FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,980,000.00 Net Margins-155.47% Pretax MarginN/A Return on Equity-74.66% Return on Assets-45.05% Debt Debt-to-Equity Ratio1.05 Current Ratio18.38 Quick Ratio3.36 Sales & Book Value Annual Sales$3.20 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares917,390,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta1.83 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Alexandra AndrewsChief Operating OfficerMr. Gerald QuigleyDirector of Public Relations & DirectorDr. Thomas Duthy M.B.A.Ph.D., Executive DirectorDr. Emanuela RussoChief Scientific Officer & Member of Scientific Advisory BoardMr. Peter James Lawrence Griffiths B.Sc. (Age 60)Chief Executive Officer of AAT Research Ltd Ms. Erlyn Saromines Dawson A.C.I.S.ACIS, AGIA, B.Com., BCom., GradDipACG, Company SecretaryMore ExecutivesKey Competitors4DMedicalASX:4DXAdheriumASX:ADRAinosNASDAQ:AIMDWAllegra Medical TechnologiesASX:AMTAnalyticaASX:ALTView All CompetitorsInsidersThomas (Tom) DuthyBought 340,000 shares on 1/29/2024Total: $30,940.00 ($0.09/share)Winton WilleseeBought 2,000,000 shares on 11/30/2023Total: $114,000.00 ($0.06/share) This page (ASX:NTI) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsJim Cramer’s “The Biggest Drug Ever”Behind the MarketsYour Money is Not SafeAmerican AlternativeThe AI stock to buy right nowStockEarningsThe only accurate crypto trading system I know …Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurotech International Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
